| __timestamp | HUTCHMED (China) Limited | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 26684000 | 612613000000 |
| Thursday, January 1, 2015 | 29829000 | 650773000000 |
| Friday, January 1, 2016 | 39578000 | 619061000000 |
| Sunday, January 1, 2017 | 43277000 | 628106000000 |
| Monday, January 1, 2018 | 48645000 | 717599000000 |
| Tuesday, January 1, 2019 | 52934000 | 964737000000 |
| Wednesday, January 1, 2020 | 61349000 | 875663000000 |
| Friday, January 1, 2021 | 127125000 | 886361000000 |
| Saturday, January 1, 2022 | 136106000 | 997309000000 |
| Sunday, January 1, 2023 | 133175999 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Unleashing insights
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Takeda Pharmaceutical Company Limited and HUTCHMED (China) Limited, two industry leaders, showcase contrasting strategies in this domain. From 2014 to 2023, Takeda's SG&A expenses have consistently been over 10,000 times higher than HUTCHMED's, reflecting its expansive global operations. However, HUTCHMED has shown a remarkable growth trajectory, with its SG&A costs increasing by approximately 400% over the same period, indicating aggressive expansion and investment in its operations.
Takeda's expenses peaked in 2023, reaching over 1 trillion, while HUTCHMED's expenses saw a significant rise in 2021, doubling from the previous year. This data highlights the different scales and strategies of these companies, with Takeda focusing on maintaining its vast operations and HUTCHMED investing heavily in growth. Missing data for 2024 suggests ongoing developments in this dynamic industry.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
Takeda Pharmaceutical Company Limited or HUTCHMED (China) Limited: Who Invests More in Innovation?
CRISPR Therapeutics AG or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and HUTCHMED (China) Limited
Selling, General, and Administrative Costs: MorphoSys AG vs HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of Catalyst Pharmaceuticals, Inc. and HUTCHMED (China) Limited
HUTCHMED (China) Limited vs ImmunityBio, Inc.: SG&A Expense Trends
HUTCHMED (China) Limited or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Viridian Therapeutics, Inc.